HIV Screening and Treatment Guidelines

HIV Screening Recommendations

• The American Academy of Family Physicians recommends that all persons aged 15-65 years should be screened for HIV at least once in their lifetime, with routine opt-out screening recommended in primary care settings, emergency departments, and for all pregnant women 1, 2
• The Centers for Disease Control and Prevention (CDC) recommends that adolescents and adults aged 15-65 years should undergo routine HIV screening regardless of perceived risk 1, 2

High-Risk Populations Requiring Frequent Screening

• The CDC recommends that high-risk individuals, including men who have sex with men (MSM), transfeminine persons, people who inject drugs, and persons newly diagnosed with sexually transmitted infections (STIs) or hepatitis C, should be tested every 3 months as long as risk continues 1
• The CDC also recommends that sexual partners of HIV-infected persons and persons who exchange sex for money or drugs should be screened frequently 3

Optimal Testing Methods

• The CDC recommends that screening should be performed with fourth-generation HIV antigen/antibody combination assays that detect both HIV antibodies and p24 antigen, allowing detection of recent infection 1, 4

Critical Testing Algorithm

• The CDC recommends that all reactive screening tests must be confirmed before diagnosis, using a combination of HIV-1/HIV-2 antibody differentiation immunoassay and HIV RNA testing if necessary 5, 6, 7, 8, 4

Post-Diagnosis Evaluation

• The American College of Physicians recommends that before starting antiretroviral therapy (ART), patients should undergo immediate laboratory assessment, including HIV RNA level, CD4 cell count, and HIV genotype resistance testing 1, 9

Antiretroviral Therapy Initiation

• The International AIDS Society-USA recommends that all persons diagnosed with HIV should be offered ART immediately, regardless of CD4 count or viral load 1, 10, 2

Monitoring During Treatment

• The CDC recommends that viral load should be measured 4-6 weeks after starting or changing ART regimen, and every 3 months until suppressed for at least 1 year 10
• The CDC also recommends that CD4 counts should be measured every 6 months until counts are >250/μL for at least 1 year with concomitant viral suppression 10

Treatment of Multidrug-Resistant HIV

• The CDC recommends that for patients with extremely limited treatment options due to multidrug resistance, ibalizumab and fostemsavir may be considered as salvage therapy options 1

Engagement in Care and Adherence

• The CDC recommends that brief, strengths-based case management after HIV diagnosis facilitates linkage to care, and systematic monitoring of time to care linkage, retention, and viral suppression is recommended in all care settings 10

Psychosocial Support

• The American Psychological Association recommends that behavioral and psychosocial services are integral to HIV care and should be available on-site or through referral 5, 7, 8
• The CDC recommends that routine screening and treatment for depression is recommended for all HIV-infected patients 10

Prevention Counseling

• The CDC recommends that post-exposure prophylaxis (PEP) should be offered to persons with high-risk exposure within the previous 72 hours, and pre-exposure prophylaxis (PrEP) should be offered to persons with ongoing high risk for HIV infection 1

HIV Screening and Management Guidelines

Introduction to Screening Approaches

• Risk-based screening has failed to identify 10-25% of HIV-positive individuals who report no high-risk behaviors, according to the American College of Physicians, highlighting the need for universal screening approaches 11, 12
• Even when risk factors are clearly documented in medical records, only one-third of at-risk patients actually receive testing, as noted by the American College of Physicians 12
• Approximately half of patients are diagnosed late in disease when they cannot receive maximum benefit from antiretroviral therapy, emphasizing the importance of early screening, as recommended by the American College of Physicians 12
• Routine opt-out screening has been highly successful for prenatal HIV screening, with high acceptance rates and near-elimination of mother-to-child transmission, according to the American College of Obstetricians and Gynecologists 11, 12

Optimal Testing and Monitoring

• The American Medical Association recommends viral load monitoring at 4-6 weeks after starting or changing antiretroviral therapy regimen, every 3 months until HIV RNA <50 copies/mL for at least 1 year, and every 6 months after achieving 1 year of viral suppression with consistent adherence 13
• The American Medical Association also recommends CD4 count monitoring every 6 months until counts are >250/μL for at least 1 year with concomitant viral suppression, which can be discontinued once this threshold is maintained 13

Screening for Co-Infections and Complications

• The American Medical Association recommends age- and risk-appropriate screening every visit for sexually transmitted infections, anal or cervical dysplasia, and depression, as well as general health and medication toxicity assessments 13

Common Pitfalls to Avoid

• The American College of Physicians advises against relying solely on patient-reported risk behaviors, as many infected individuals either don't recognize their risk or won't disclose behaviors, and against delaying testing in low-prevalence settings, as screening is cost-effective even at prevalence as low as 0.1-0.2% 11, 12

HIV Screening Recommendations (Evidence‑Based)

Universal Age‑Based Screening

• The CDC and USPSTF recommend opt‑out HIV screening for all individuals aged 13–65 years (CDC) or 15–65 years (USPSTF); using the broader 13–65 year range ensures capture of all at‑risk adolescents. 14
• All patients 15–65 years should be screened at least once in their lifetime in any healthcare setting (primary care, emergency, urgent care, inpatient, STD, TB, correctional). This recommendation is supported by the CDC’s 2006 guidance and reinforced in a 2013 systematic review. 14, 15

Opt‑Out Screening Approach

• Patients must be informed (orally or in writing) that HIV testing will be performed as routine care unless they decline, eliminating the need for separate written consent or extensive pre‑test counseling. 14

High‑Risk Populations Requiring More Frequent Testing

Annual Screening (minimum)

• Annual HIV testing is advised for persons at high risk, including:
  
  • Injection drug users and their sexual partners
  • Individuals who exchange sex for money or drugs
  • Sexual partners of known HIV‑infected persons
  • Heterosexual persons (or partners) with more than one sexual partner since their last HIV test
  • (All groups cited in CDC 2006 recommendations). 14

Every‑3‑Month Screening (highest risk)

• Screen every 3 months for the highest‑risk groups while risk persists, specifically men who have sex with men (MSM) who have multiple or anonymous partners. 14

Special Populations

• Pregnant women should be screened for HIV during each pregnancy, ideally at the first prenatal visit. 14
• All patients initiating treatment for tuberculosis must receive routine HIV screening. 14
• Patients seeking evaluation for a sexually transmitted infection should be screened at every visit for a new complaint, regardless of disclosed risk behaviors. 14

Screening Frequency in Average‑Risk Individuals

• One‑time screening is the minimum standard for all persons 15–65 years; repeat testing should be guided by clinical judgment (e.g., new sexual relationships, changes in partnership status, or patient request). 14
• Clinicians should encourage patients and prospective partners to undergo HIV testing before initiating a new sexual relationship. 14

Prevalence Thresholds Guiding Routine Screening

• Routine opt‑out screening should be implemented unless the undiagnosed HIV prevalence in the target population is documented to be <0.1 % (i.e., fewer than 1 case per 1,000 persons). This threshold is supported by CDC 2006 guidance and a 2013 cost‑effectiveness analysis. 14, 15
• When prevalence data are unavailable, voluntary screening should continue until the diagnostic yield is shown to be <1 per 1,000 screened. 14

Limitations of Risk‑Based Screening

• Risk‑based approaches miss 10–25 % of HIV‑positive individuals who report no high‑risk behaviors, highlighting the superiority of universal opt‑out testing. 16

Clinical Benefits of Early Detection

• Early identification of HIV infection followed by antiretroviral therapy markedly reduces AIDS‑related events, mortality, and sexual transmission to uninfected partners. This benefit is documented in a 2013 systematic review. 15

All facts are derived from cited sources (CDC MMWR 2006, Annals of Internal Medicine 2013, Annals of Internal Medicine 2009) and reflect the strength of evidence as presented in those guideline documents.